PARP1 and Ewing sarcoma: Ewing’s sarcoma cells exhibit high levels of DNA damage and similarity in phenotype to BRCA1/2 mutant breast cancer, providing a molecular basis for the high sensitivity of Ewing’s sarcoma to PARP1 inhibitors [5, 6].